nodes	percent_of_prediction	percent_of_DWPC	metapath
Alpha-Linolenic Acid—TRPV1—urinary bladder cancer	0.861	1	CbGaD
Alpha-Linolenic Acid—FABP3—prostate gland—urinary bladder cancer	0.00735	0.0734	CbGeAlD
Alpha-Linolenic Acid—ELOVL4—prostate gland—urinary bladder cancer	0.00655	0.0654	CbGeAlD
Alpha-Linolenic Acid—FADS2—prostate gland—urinary bladder cancer	0.00557	0.0556	CbGeAlD
Alpha-Linolenic Acid—FABP3—renal system—urinary bladder cancer	0.00501	0.05	CbGeAlD
Alpha-Linolenic Acid—SLC8A1—smooth muscle tissue—urinary bladder cancer	0.00464	0.0463	CbGeAlD
Alpha-Linolenic Acid—SLC8A1—renal system—urinary bladder cancer	0.00447	0.0446	CbGeAlD
Alpha-Linolenic Acid—ELOVL4—urethra—urinary bladder cancer	0.00439	0.0438	CbGeAlD
Alpha-Linolenic Acid—FADS1—prostate gland—urinary bladder cancer	0.00437	0.0437	CbGeAlD
Alpha-Linolenic Acid—FADS2—epithelium—urinary bladder cancer	0.0041	0.0409	CbGeAlD
Alpha-Linolenic Acid—FABP3—female reproductive system—urinary bladder cancer	0.00401	0.0401	CbGeAlD
Alpha-Linolenic Acid—FADS2—smooth muscle tissue—urinary bladder cancer	0.00395	0.0394	CbGeAlD
Alpha-Linolenic Acid—FADS2—renal system—urinary bladder cancer	0.0038	0.0379	CbGeAlD
Alpha-Linolenic Acid—FADS2—urethra—urinary bladder cancer	0.00373	0.0372	CbGeAlD
Alpha-Linolenic Acid—FADS1—seminal vesicle—urinary bladder cancer	0.0037	0.0369	CbGeAlD
Alpha-Linolenic Acid—SLC8A1—female reproductive system—urinary bladder cancer	0.00358	0.0357	CbGeAlD
Alpha-Linolenic Acid—Icosapent—TRPV1—urinary bladder cancer	0.00347	0.606	CrCbGaD
Alpha-Linolenic Acid—ELOVL4—vagina—urinary bladder cancer	0.00324	0.0323	CbGeAlD
Alpha-Linolenic Acid—TRPV1—epithelium—urinary bladder cancer	0.00321	0.0321	CbGeAlD
Alpha-Linolenic Acid—FADS1—smooth muscle tissue—urinary bladder cancer	0.0031	0.0309	CbGeAlD
Alpha-Linolenic Acid—FADS2—female reproductive system—urinary bladder cancer	0.00304	0.0304	CbGeAlD
Alpha-Linolenic Acid—TRPV1—renal system—urinary bladder cancer	0.00298	0.0298	CbGeAlD
Alpha-Linolenic Acid—FADS1—urethra—urinary bladder cancer	0.00293	0.0292	CbGeAlD
Alpha-Linolenic Acid—FABP7—female reproductive system—urinary bladder cancer	0.00263	0.0263	CbGeAlD
Alpha-Linolenic Acid—TRPV1—female reproductive system—urinary bladder cancer	0.00239	0.0238	CbGeAlD
Alpha-Linolenic Acid—FADS1—vagina—urinary bladder cancer	0.00216	0.0216	CbGeAlD
Alpha-Linolenic Acid—ELOVL4—lymph node—urinary bladder cancer	0.00209	0.0209	CbGeAlD
Alpha-Linolenic Acid—FADS2—lymph node—urinary bladder cancer	0.00178	0.0178	CbGeAlD
Alpha-Linolenic Acid—FADS1—lymph node—urinary bladder cancer	0.0014	0.0139	CbGeAlD
Alpha-Linolenic Acid—Icosapent—PPARG—urinary bladder cancer	0.00115	0.201	CrCbGaD
Alpha-Linolenic Acid—SLC8A1—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.00071	0.0281	CbGpPWpGaD
Alpha-Linolenic Acid—Dihomo-gamma-linolenic acid—PTGS2—urinary bladder cancer	0.000619	0.108	CrCbGaD
Alpha-Linolenic Acid—FADS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000618	0.0244	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000494	0.0195	CbGpPWpGaD
Alpha-Linolenic Acid—Icosapent—PTGS2—urinary bladder cancer	0.000486	0.0849	CrCbGaD
Alpha-Linolenic Acid—SLC8A1—Myometrial Relaxation and Contraction Pathways—IGFBP3—urinary bladder cancer	0.000467	0.0185	CbGpPWpGaD
Alpha-Linolenic Acid—TRPV1—Trk receptor signaling mediated by PI3K and PLC-gamma—CCND1—urinary bladder cancer	0.00046	0.0182	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—PPARA activates gene expression—NCOR1—urinary bladder cancer	0.000458	0.0181	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NCOR1—urinary bladder cancer	0.000448	0.0177	CbGpPWpGaD
Alpha-Linolenic Acid—TRPV1—Trk receptor signaling mediated by PI3K and PLC-gamma—SRC—urinary bladder cancer	0.000412	0.0163	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	0.000408	0.0161	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000374	0.0148	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000361	0.0143	CbGpPWpGaD
Alpha-Linolenic Acid—TRPV1—Trk receptor signaling mediated by the MAPK pathway—KRAS—urinary bladder cancer	0.000357	0.0141	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—GSTZ1—urinary bladder cancer	0.000353	0.0139	CbGpPWpGaD
Alpha-Linolenic Acid—TRPV1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000348	0.0138	CbGpPWpGaD
Alpha-Linolenic Acid—TRPV1—Trk receptor signaling mediated by PI3K and PLC-gamma—KRAS—urinary bladder cancer	0.000341	0.0135	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—GSTO2—urinary bladder cancer	0.000334	0.0132	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—NAT1—urinary bladder cancer	0.000334	0.0132	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000329	0.013	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—PPARA activates gene expression—PPARG—urinary bladder cancer	0.000328	0.013	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—urinary bladder cancer	0.000321	0.0127	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—PPARA activates gene expression—CREBBP—urinary bladder cancer	0.000315	0.0125	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	0.000309	0.0122	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	0.000309	0.0122	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—UGT2B7—urinary bladder cancer	0.000306	0.0121	CbGpPWpGaD
Alpha-Linolenic Acid—TRPV1—Trk receptor signaling mediated by the MAPK pathway—HRAS—urinary bladder cancer	0.000303	0.012	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	0.000292	0.0115	CbGpPWpGaD
Alpha-Linolenic Acid—TRPV1—Trk receptor signaling mediated by PI3K and PLC-gamma—HRAS—urinary bladder cancer	0.00029	0.0114	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—GSTZ1—urinary bladder cancer	0.000282	0.0111	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	0.000281	0.0111	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—CYP4B1—urinary bladder cancer	0.000275	0.0109	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—GSTO2—urinary bladder cancer	0.000267	0.0106	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—NAT1—urinary bladder cancer	0.000267	0.0106	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000263	0.0104	CbGpPWpGaD
Alpha-Linolenic Acid—Pruritus—Valrubicin—urinary bladder cancer	0.000262	0.0343	CcSEcCtD
Alpha-Linolenic Acid—SLC8A1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000261	0.0103	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—SLC19A1—urinary bladder cancer	0.00026	0.0103	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—PRSS3—urinary bladder cancer	0.000253	0.01	CbGpPWpGaD
Alpha-Linolenic Acid—TRPV1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000252	0.00995	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—UGT2B7—urinary bladder cancer	0.000244	0.00965	CbGpPWpGaD
Alpha-Linolenic Acid—Vomiting—Valrubicin—urinary bladder cancer	0.000235	0.0308	CcSEcCtD
Alpha-Linolenic Acid—Aspartate aminotransferase increased—Thiotepa—urinary bladder cancer	0.000235	0.0307	CcSEcCtD
Alpha-Linolenic Acid—Rash—Valrubicin—urinary bladder cancer	0.000233	0.0305	CcSEcCtD
Alpha-Linolenic Acid—Dermatitis—Valrubicin—urinary bladder cancer	0.000233	0.0305	CcSEcCtD
Alpha-Linolenic Acid—Alanine aminotransferase increased—Thiotepa—urinary bladder cancer	0.00023	0.0301	CcSEcCtD
Alpha-Linolenic Acid—FADS1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	0.000221	0.00875	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—CYP4B1—urinary bladder cancer	0.00022	0.00869	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—PPARA activates gene expression—EP300—urinary bladder cancer	0.000215	0.00849	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—GSTZ1—urinary bladder cancer	0.000214	0.00844	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	0.000213	0.0084	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000213	0.0084	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	0.00021	0.00831	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—SLC19A1—urinary bladder cancer	0.000208	0.00821	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Ectoderm Differentiation—MYC—urinary bladder cancer	0.000206	0.00814	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000203	0.00802	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—PRSS3—urinary bladder cancer	0.000202	0.008	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—GSTO2—urinary bladder cancer	0.000202	0.008	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—NAT1—urinary bladder cancer	0.000202	0.008	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—TYMP—urinary bladder cancer	0.000202	0.008	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000199	0.00787	CbGpPWpGaD
Alpha-Linolenic Acid—Aspartate aminotransferase increased—Gemcitabine—urinary bladder cancer	0.000198	0.0259	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000194	0.00768	CbGpPWpGaD
Alpha-Linolenic Acid—Alanine aminotransferase increased—Gemcitabine—urinary bladder cancer	0.000194	0.0253	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000191	0.00755	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—UGT2B7—urinary bladder cancer	0.000185	0.00732	CbGpPWpGaD
Alpha-Linolenic Acid—Aspartate aminotransferase increased—Cisplatin—urinary bladder cancer	0.000184	0.0241	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism—NAT2—urinary bladder cancer	0.000183	0.00723	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—CYP4B1—urinary bladder cancer	0.000167	0.00659	CbGpPWpGaD
Alpha-Linolenic Acid—Alanine aminotransferase increased—Etoposide—urinary bladder cancer	0.000165	0.0216	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000162	0.00641	CbGpPWpGaD
Alpha-Linolenic Acid—Vomiting—Mitomycin—urinary bladder cancer	0.000162	0.0212	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism—TYMP—urinary bladder cancer	0.000162	0.00639	CbGpPWpGaD
Alpha-Linolenic Acid—Rash—Mitomycin—urinary bladder cancer	0.000161	0.021	CcSEcCtD
Alpha-Linolenic Acid—Dermatitis—Mitomycin—urinary bladder cancer	0.000161	0.021	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism—RRM2—urinary bladder cancer	0.000158	0.00624	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—SLC19A1—urinary bladder cancer	0.000157	0.00622	CbGpPWpGaD
Alpha-Linolenic Acid—Malnutrition—Thiotepa—urinary bladder cancer	0.000157	0.0206	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000155	0.00614	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—PRSS3—urinary bladder cancer	0.000153	0.00606	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—HPGDS—urinary bladder cancer	0.000146	0.00578	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—ENO2—urinary bladder cancer	0.000146	0.00578	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—NAT2—urinary bladder cancer	0.000146	0.00578	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000146	0.00575	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000145	0.00572	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000144	0.00567	CbGpPWpGaD
Alpha-Linolenic Acid—Eructation—Epirubicin—urinary bladder cancer	0.000142	0.0186	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism—GSTT1—urinary bladder cancer	0.000142	0.00561	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.00014	0.00552	CbGpPWpGaD
Alpha-Linolenic Acid—TRPV1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000139	0.00548	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—IFNA2—urinary bladder cancer	0.000133	0.00524	CbGpPWpGaD
Alpha-Linolenic Acid—Eructation—Doxorubicin—urinary bladder cancer	0.000132	0.0172	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism—RRM2—urinary bladder cancer	0.000126	0.00499	CbGpPWpGaD
Alpha-Linolenic Acid—Malnutrition—Cisplatin—urinary bladder cancer	0.000123	0.0161	CcSEcCtD
Alpha-Linolenic Acid—FADS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000123	0.00486	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—TYMP—urinary bladder cancer	0.000123	0.00485	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—NQO1—urinary bladder cancer	0.000118	0.00466	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000118	0.00465	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—HPGDS—urinary bladder cancer	0.000117	0.00462	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—ENO2—urinary bladder cancer	0.000117	0.00462	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000116	0.0046	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000114	0.00452	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—GSTT1—urinary bladder cancer	0.000114	0.00448	CbGpPWpGaD
Alpha-Linolenic Acid—Dyspepsia—Thiotepa—urinary bladder cancer	0.000113	0.0148	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000112	0.00442	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—NAT2—urinary bladder cancer	0.000111	0.00438	CbGpPWpGaD
Alpha-Linolenic Acid—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000111	0.0145	CcSEcCtD
Alpha-Linolenic Acid—Dysgeusia—Etoposide—urinary bladder cancer	0.00011	0.0145	CcSEcCtD
Alpha-Linolenic Acid—Constipation—Thiotepa—urinary bladder cancer	0.00011	0.0144	CcSEcCtD
Alpha-Linolenic Acid—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000108	0.0141	CcSEcCtD
Alpha-Linolenic Acid—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000106	0.0139	CcSEcCtD
Alpha-Linolenic Acid—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000101	0.0132	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.98e-05	0.00394	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—GSTP1—urinary bladder cancer	9.84e-05	0.00389	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—RRM2—urinary bladder cancer	9.58e-05	0.00378	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.52e-05	0.00376	CbGpPWpGaD
Alpha-Linolenic Acid—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	9.46e-05	0.0124	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism—NQO1—urinary bladder cancer	9.43e-05	0.00373	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—PLAU—urinary bladder cancer	9.41e-05	0.00372	CbGpPWpGaD
Alpha-Linolenic Acid—Dyspepsia—Fluorouracil—urinary bladder cancer	9.33e-05	0.0122	CcSEcCtD
Alpha-Linolenic Acid—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	9.31e-05	0.0122	CcSEcCtD
Alpha-Linolenic Acid—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	9.26e-05	0.0121	CcSEcCtD
Alpha-Linolenic Acid—Constipation—Gemcitabine—urinary bladder cancer	9.22e-05	0.0121	CcSEcCtD
Alpha-Linolenic Acid—Anaphylactic shock—Etoposide—urinary bladder cancer	9.21e-05	0.0121	CcSEcCtD
Alpha-Linolenic Acid—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	9.15e-05	0.012	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.15e-05	0.00362	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—TYMS—urinary bladder cancer	9.15e-05	0.00361	CbGpPWpGaD
Alpha-Linolenic Acid—Pruritus—Thiotepa—urinary bladder cancer	9.07e-05	0.0119	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism—NCOR1—urinary bladder cancer	9.04e-05	0.00357	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—GSTM1—urinary bladder cancer	9.04e-05	0.00357	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—ENO2—urinary bladder cancer	8.87e-05	0.0035	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—HPGDS—urinary bladder cancer	8.87e-05	0.0035	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.82e-05	0.00348	CbGpPWpGaD
Alpha-Linolenic Acid—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	8.75e-05	0.0115	CcSEcCtD
Alpha-Linolenic Acid—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	8.68e-05	0.0114	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism—GPX1—urinary bladder cancer	8.66e-05	0.00342	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—GSTT1—urinary bladder cancer	8.6e-05	0.0034	CbGpPWpGaD
Alpha-Linolenic Acid—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	8.57e-05	0.0112	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism—ERCC2—urinary bladder cancer	8.5e-05	0.00336	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.47e-05	0.00335	CbGpPWpGaD
Alpha-Linolenic Acid—Vomiting—Thiotepa—urinary bladder cancer	8.15e-05	0.0107	CcSEcCtD
Alpha-Linolenic Acid—Rash—Thiotepa—urinary bladder cancer	8.08e-05	0.0106	CcSEcCtD
Alpha-Linolenic Acid—Dermatitis—Thiotepa—urinary bladder cancer	8.08e-05	0.0106	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism—MTHFR—urinary bladder cancer	7.99e-05	0.00316	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.98e-05	0.00315	CbGpPWpGaD
Alpha-Linolenic Acid—Gastrointestinal disorder—Etoposide—urinary bladder cancer	7.95e-05	0.0104	CcSEcCtD
Alpha-Linolenic Acid—Constipation—Etoposide—urinary bladder cancer	7.87e-05	0.0103	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism—GSTP1—urinary bladder cancer	7.87e-05	0.00311	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—CREBBP—urinary bladder cancer	7.77e-05	0.00307	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—IGF1—urinary bladder cancer	7.67e-05	0.00303	CbGpPWpGaD
Alpha-Linolenic Acid—Pruritus—Gemcitabine—urinary bladder cancer	7.63e-05	0.00999	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.61e-05	0.00301	CbGpPWpGaD
Alpha-Linolenic Acid—Pruritus—Fluorouracil—urinary bladder cancer	7.5e-05	0.00982	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism—TYMS—urinary bladder cancer	7.31e-05	0.00289	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—GSTM1—urinary bladder cancer	7.23e-05	0.00286	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—NCOR1—urinary bladder cancer	7.23e-05	0.00286	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—NQO1—urinary bladder cancer	7.15e-05	0.00282	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—RHOA—urinary bladder cancer	7.03e-05	0.00278	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.94e-05	0.00274	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—GPX1—urinary bladder cancer	6.92e-05	0.00274	CbGpPWpGaD
Alpha-Linolenic Acid—Vomiting—Gemcitabine—urinary bladder cancer	6.86e-05	0.00898	CcSEcCtD
Alpha-Linolenic Acid—Rash—Gemcitabine—urinary bladder cancer	6.8e-05	0.0089	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism—ERCC2—urinary bladder cancer	6.8e-05	0.00269	CbGpPWpGaD
Alpha-Linolenic Acid—Dermatitis—Gemcitabine—urinary bladder cancer	6.79e-05	0.00889	CcSEcCtD
Alpha-Linolenic Acid—Malnutrition—Methotrexate—urinary bladder cancer	6.76e-05	0.00885	CcSEcCtD
Alpha-Linolenic Acid—Vomiting—Fluorouracil—urinary bladder cancer	6.74e-05	0.00882	CcSEcCtD
Alpha-Linolenic Acid—SLC8A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.72e-05	0.00266	CbGpPWpGaD
Alpha-Linolenic Acid—Rash—Fluorouracil—urinary bladder cancer	6.69e-05	0.00875	CcSEcCtD
Alpha-Linolenic Acid—Dermatitis—Fluorouracil—urinary bladder cancer	6.68e-05	0.00874	CcSEcCtD
Alpha-Linolenic Acid—Dysgeusia—Methotrexate—urinary bladder cancer	6.62e-05	0.00866	CcSEcCtD
Alpha-Linolenic Acid—Pruritus—Etoposide—urinary bladder cancer	6.51e-05	0.00853	CcSEcCtD
Alpha-Linolenic Acid—TRPV1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.49e-05	0.00256	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—PPARG—urinary bladder cancer	6.48e-05	0.00256	CbGpPWpGaD
Alpha-Linolenic Acid—Vomiting—Cisplatin—urinary bladder cancer	6.39e-05	0.00837	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism—MTHFR—urinary bladder cancer	6.39e-05	0.00252	CbGpPWpGaD
Alpha-Linolenic Acid—Rash—Cisplatin—urinary bladder cancer	6.34e-05	0.0083	CcSEcCtD
Alpha-Linolenic Acid—Dermatitis—Cisplatin—urinary bladder cancer	6.33e-05	0.00829	CcSEcCtD
Alpha-Linolenic Acid—Malnutrition—Epirubicin—urinary bladder cancer	6.32e-05	0.00828	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism—CREBBP—urinary bladder cancer	6.23e-05	0.00246	CbGpPWpGaD
Alpha-Linolenic Acid—Dysgeusia—Epirubicin—urinary bladder cancer	6.19e-05	0.00811	CcSEcCtD
Alpha-Linolenic Acid—FADS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.05e-05	0.00239	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—GSTP1—urinary bladder cancer	5.96e-05	0.00236	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—IL2—urinary bladder cancer	5.89e-05	0.00233	CbGpPWpGaD
Alpha-Linolenic Acid—Vomiting—Etoposide—urinary bladder cancer	5.85e-05	0.00766	CcSEcCtD
Alpha-Linolenic Acid—Malnutrition—Doxorubicin—urinary bladder cancer	5.85e-05	0.00766	CcSEcCtD
Alpha-Linolenic Acid—Rash—Etoposide—urinary bladder cancer	5.81e-05	0.0076	CcSEcCtD
Alpha-Linolenic Acid—Dermatitis—Etoposide—urinary bladder cancer	5.8e-05	0.00759	CcSEcCtD
Alpha-Linolenic Acid—FADS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.77e-05	0.00228	CbGpPWpGaD
Alpha-Linolenic Acid—Dysgeusia—Doxorubicin—urinary bladder cancer	5.73e-05	0.0075	CcSEcCtD
Alpha-Linolenic Acid—FADS1—Metabolism—TYMS—urinary bladder cancer	5.54e-05	0.00219	CbGpPWpGaD
Alpha-Linolenic Acid—Anaphylactic shock—Methotrexate—urinary bladder cancer	5.52e-05	0.00722	CcSEcCtD
Alpha-Linolenic Acid—FADS1—Metabolism—NCOR1—urinary bladder cancer	5.48e-05	0.00216	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—GSTM1—urinary bladder cancer	5.48e-05	0.00216	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—EP300—urinary bladder cancer	5.29e-05	0.00209	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—GPX1—urinary bladder cancer	5.25e-05	0.00207	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—PPARG—urinary bladder cancer	5.18e-05	0.00205	CbGpPWpGaD
Alpha-Linolenic Acid—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.16e-05	0.00676	CcSEcCtD
Alpha-Linolenic Acid—FADS1—Metabolism—ERCC2—urinary bladder cancer	5.15e-05	0.00204	CbGpPWpGaD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—SRC—urinary bladder cancer	5.14e-05	0.00203	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—PTGS2—urinary bladder cancer	5.1e-05	0.00201	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—CREBBP—urinary bladder cancer	4.98e-05	0.00197	CbGpPWpGaD
Alpha-Linolenic Acid—Dyspepsia—Methotrexate—urinary bladder cancer	4.86e-05	0.00636	CcSEcCtD
Alpha-Linolenic Acid—FADS1—Metabolism—MTHFR—urinary bladder cancer	4.84e-05	0.00191	CbGpPWpGaD
Alpha-Linolenic Acid—Anaphylactic shock—Doxorubicin—urinary bladder cancer	4.78e-05	0.00625	CcSEcCtD
Alpha-Linolenic Acid—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	4.76e-05	0.00623	CcSEcCtD
Alpha-Linolenic Acid—Dyspepsia—Epirubicin—urinary bladder cancer	4.54e-05	0.00595	CcSEcCtD
Alpha-Linolenic Acid—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.46e-05	0.00583	CcSEcCtD
Alpha-Linolenic Acid—FADS2—Metabolism—PTEN—urinary bladder cancer	4.45e-05	0.00176	CbGpPWpGaD
Alpha-Linolenic Acid—Constipation—Epirubicin—urinary bladder cancer	4.41e-05	0.00578	CcSEcCtD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—KRAS—urinary bladder cancer	4.26e-05	0.00168	CbGpPWpGaD
Alpha-Linolenic Acid—FADS2—Metabolism—EP300—urinary bladder cancer	4.24e-05	0.00168	CbGpPWpGaD
Alpha-Linolenic Acid—Dyspepsia—Doxorubicin—urinary bladder cancer	4.2e-05	0.0055	CcSEcCtD
Alpha-Linolenic Acid—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.12e-05	0.0054	CcSEcCtD
Alpha-Linolenic Acid—Constipation—Doxorubicin—urinary bladder cancer	4.08e-05	0.00535	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism—PTGS2—urinary bladder cancer	4.08e-05	0.00161	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—PPARG—urinary bladder cancer	3.93e-05	0.00155	CbGpPWpGaD
Alpha-Linolenic Acid—Pruritus—Methotrexate—urinary bladder cancer	3.9e-05	0.00511	CcSEcCtD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—TP53—urinary bladder cancer	3.78e-05	0.0015	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—CREBBP—urinary bladder cancer	3.77e-05	0.00149	CbGpPWpGaD
Alpha-Linolenic Acid—Pruritus—Epirubicin—urinary bladder cancer	3.65e-05	0.00478	CcSEcCtD
Alpha-Linolenic Acid—SLC8A1—Hemostasis—HRAS—urinary bladder cancer	3.62e-05	0.00143	CbGpPWpGaD
Alpha-Linolenic Acid—ELOVL4—Metabolism—PTEN—urinary bladder cancer	3.55e-05	0.0014	CbGpPWpGaD
Alpha-Linolenic Acid—Vomiting—Methotrexate—urinary bladder cancer	3.51e-05	0.00459	CcSEcCtD
Alpha-Linolenic Acid—Rash—Methotrexate—urinary bladder cancer	3.48e-05	0.00455	CcSEcCtD
Alpha-Linolenic Acid—Dermatitis—Methotrexate—urinary bladder cancer	3.47e-05	0.00455	CcSEcCtD
Alpha-Linolenic Acid—ELOVL4—Metabolism—EP300—urinary bladder cancer	3.39e-05	0.00134	CbGpPWpGaD
Alpha-Linolenic Acid—Pruritus—Doxorubicin—urinary bladder cancer	3.38e-05	0.00442	CcSEcCtD
Alpha-Linolenic Acid—Vomiting—Epirubicin—urinary bladder cancer	3.28e-05	0.0043	CcSEcCtD
Alpha-Linolenic Acid—Rash—Epirubicin—urinary bladder cancer	3.25e-05	0.00426	CcSEcCtD
Alpha-Linolenic Acid—Dermatitis—Epirubicin—urinary bladder cancer	3.25e-05	0.00426	CcSEcCtD
Alpha-Linolenic Acid—FADS1—Metabolism—PTGS2—urinary bladder cancer	3.09e-05	0.00122	CbGpPWpGaD
Alpha-Linolenic Acid—Vomiting—Doxorubicin—urinary bladder cancer	3.04e-05	0.00398	CcSEcCtD
Alpha-Linolenic Acid—Rash—Doxorubicin—urinary bladder cancer	3.01e-05	0.00394	CcSEcCtD
Alpha-Linolenic Acid—Dermatitis—Doxorubicin—urinary bladder cancer	3.01e-05	0.00394	CcSEcCtD
Alpha-Linolenic Acid—FADS1—Metabolism—PTEN—urinary bladder cancer	2.69e-05	0.00106	CbGpPWpGaD
Alpha-Linolenic Acid—FADS1—Metabolism—EP300—urinary bladder cancer	2.57e-05	0.00101	CbGpPWpGaD
